cyclin e2和survivin在急性白血病的表达及其相关性论文

《cyclin e2和survivin在急性白血病的表达及其相关性论文》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、CyclinE2和Survivin在急性白血病的表达及其相关性论文.freelRNA的表达。结果表明：①cyclinE2在急性白血病中表达的阳性率（70.24％）高于对照组（0％）；survivin在急性白血病中表达的阳性率（72.62％）高于对照组（30％）；②在急性白血病中cyclinE2的表达与survivin的表达呈正相关性，r＝0.65；③cyclinE2阳性组缓解率（55.81％）低于cyclinE2阴性组（88.24％）.freelalignanthemophaty，acuteleukemia(AL)，especially，acutelymphocyticleuk

2、emia（ALL）underprovementinclinicaloutebenefitedfromthedevelopmentofhematopoieticstemcelltransplantation(HSCT)andchemicaltherapy.PreventingrelapseandprolongingDFSstillisthefocusofALtherapy.Minimalresidualdisease(MRD)becameaneffectiveindicationforthefoundationofpost-remissiontherapyregulationsi

3、ncetheroutinemorphologicalexaminationoftheperipheralbloodandbonemarroplefromtheremissionpatiental.ButthefusiongenesuchasAML1/MTG8andPML/RARαasMRDmarker，arkerforleukemia.Ontheotherhand，RNAinterference(RNAi)asaneor-specificRNAiisiatherapy.Recently，asatypeofG1cyclin，cyclinE2arkeroftumorssinceit

4、presentedapositiveexpressioninthecelllinesofsolidtumorsandanegativeexpressioninproliferatingnormalcells［2］.Hoerasechainreaction(RT-PCR)isadoptedtotesttheexpressionofcyclinE2andsurvivinmRNAin84adultpatientsalpersonsascontrolsandleukemiacelllineK562.Subsequently，inarytheoreticalbasisforsearchi

5、nganearker.MaterialsandMethodsPatientsenrolled84adultinpatientsApril2002toMarch2003intheSecondAffiliatedHospitalofHebeiMedicalUniversityalesand34females，14-62yearsold(meanof34.1years)］edbymorphological，cytochemicalandimmunologicmarkeranalysis.AccordingtotheFrench-American-British(FAB)classif

6、ication，59patientsyelocyticleukemia(AML)，including2casesofM1，12casesofM2，21casesofM3，11casesofM4，11casesofM5，1casesofM6，1casesofM7.25patientsphocyticleukemia(ALL)including4casesofL1，19casesofL2，2casesofL3;60patientsission(CCR)(timeofdisease-freesurvival≥3years).20normalpersonsaged15-60years(

7、meanof35yearsold)containing11malesand9femalesservedascontrols.Treatments:allthesepatientsen(cytarabinearabinoside150mg/m2for7days，daunorubicin40mg/m2for3daysandetoposide75mg/m2for3days-7days).Patientsg/day)andarsenictrioxide(10mg/day)asremissionind